🔗 Visit the ClinicalTrials.gov page for NCT01838200
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Trial Watch: Toll-like receptor agonists for cancer therapy. | Oncoimmunology | 2013 | 1.35 |
| 2 | Intratumoral immunization: a new paradigm for cancer therapy. | Clin Cancer Res | 2014 | 1.24 |
| 3 | Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. | Oncoimmunology | 2014 | 1.22 |
| 4 | Checkpoint modulation in melanoma: an update on ipilimumab and future directions. | Curr Oncol Rep | 2013 | 0.94 |
| 5 | Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer. | Bladder Cancer | 2016 | 0.79 |
| 6 | Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer? | Oncoimmunology | 2015 | 0.78 |
| 7 | Adding fuel to the fire: immunogenic intensification. | Hum Vaccin Immunother | 2014 | 0.75 |
| 8 | Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management. | Hum Vaccin Immunother | 2016 | 0.75 |